REVIEW ARTICLE
Role of Genes and Treatments for Parkinson’s Disease
Falaq Naz1, Yasir Hasan Siddique1, *
Article Information
Identifiers and Pagination:
Year: 2020Volume: 8
First Page: 47
Last Page: 65
Publisher Id: TOBIOJ-8-47
DOI: 10.2174/1874196702008010047
Article History:
Received Date: 18/4/2020Revision Received Date: 6/8/2020
Acceptance Date: 24/8/2020
Electronic publication date: 15/10/2020
Collection year: 2020
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Parkinson’s Disease (PD) is a complex neurodegenerative disorder that mainly results due to the loss of dopaminergic neurons in the substantia nigra of the midbrain. It is well known that dopamine is synthesized in substantia nigra and is transported to the striatum via nigrostriatal tract. Besides the sporadic forms of PD, there are also familial cases of PD and number of genes (both autosomal dominant as well as recessive) are responsible for PD. There is no permanent cure for PD and to date, L-dopa therapy is considered to be the best option besides having dopamine agonists. In the present review, we have described the genes responsible for PD, the role of dopamine, and treatment strategies adopted for controlling the progression of PD in humans.